Silverarc Capital Management »

Acelyrin shares owned by Silverarc Capital Management

Quarter-by-quarter ownership of Acelyrin (SLRN) shares owned by Silverarc Capital Management from 13F filings

Historical chart of Silverarc Capital Management investment in Acelyrin

Tip: Access up to 7 years of quarterly data

All positions including Acelyrin held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Acelyrin by Silverarc Capital Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $234k 23k 10.17

More positions owned by Silverarc Capital Management

ImmunoGen Long Option Calls Call Option
SPRD S&P Biotech ETF Long Option Calls Call Option (XBI)
Akero Therapeutics Long Option Calls Call Option (AKRO)
Mirati Therapeutics Long Option Calls Call Option
Morphic Holding Equities (MORF)
Merus NV Equities (MRUS)
CymaBay Therapeutics Long Option Calls Call Option
Soleno Therapeutics Equities (SLNO)
Intra-Cellular Therapies Equities (ITCI)
Poseida Therapeutics Equities (PSTX)
Krystal Biotech Equities (KRYS)
Mersana Therapeutics Long Option Calls Call Option (MRSN)
KalVista Pharmaceuticals Long Option Calls Call Option (KALV)
Biogen Idec Equities (BIIB)
Urogen Pharma Equities (URGN)

View all positions for Silverarc Capital Management

Top funds holding Acelyrin

Citadel Advisors
Vanguard Group
Opaleye Management
OrbiMed Advisors
venBio Partners
Jpmorgan Chase & Co
Artal Group
Samsara BioCapital
Ikarian Capital
Blue Owl Capital Holdings
Henderson Group
Decheng Capital
Logos Global Management
Kynam Capital Management
Goldman Sachs Group

View all funds holding Acelyrin